Chun 2014.

Methods	RCT Open‐label Loss to follow‐up reported: yes
Participants	Persistent AF (mean duration: NS, in 38% of participants it was > 1 year). n = 100 Men: 81% Age (mean): 59 (SD 10) years Structural heart disease: NS. Mean LAD: 44 mm. Mean LVEF: 58%
Interventions	Dronedarone 800 mg/day vs propafenone 450 mg/day Method of AF cardioversion: electrical Warfarin (or direct oral anticoagulants) discretionary, but 94% of participants were taking anticoagulants.
Outcomes	At 6 months: AF recurrence
Notes	We tried to contact authors of this study to request additional details on methods employed and outcomes analysed.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as randomised but procedure was not described.
Allocation concealment (selection bias)	Unclear risk	Procedure to conceal allocations not described.
Blinding (performance bias and detection bias) All outcomes	High risk	Open‐label study.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Few withdrawals happened, balanced and well described.
Selective reporting (reporting bias)	High risk	The only prespecified outcome was AF recurrence, and it was adequately reported. However, other important clinical outcomes, such as adverse events and deaths, would be expected in this type of study.
Other bias	Low risk	No other bias apparent.